Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 6/20 | 0.65 |
| ▸ | DRD2 | P14416 | 5/20 | 0.65 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.58 |
| ▸ | CCR2 | P41597 | 1/20 | 0.57 |
| ▸ | BACE1 | P56817 | 3/20 | 0.57 |
| ▸ | BCHE | P06276 | 2/20 | 0.57 |
| ▸ | ACHE | P22303 | 2/20 | 0.57 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.57 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.56 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.56 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.56 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.56 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4390012 | 1.00 | DRD4 (0.65) | DRD4DRD2SIGMAR1CCR2BACE1 | |
| SCHEMBL5402061 | 0.92 | SIGMAR1 (0.68) | DRD4DRD2SIGMAR1MCHR1DPP7 | |
| SCHEMBL239528 | 0.86 | DRD4 (0.71) | DRD4DRD2SIGMAR1BACE1BCHE | |
| SCHEMBL239527 | 0.86 | DRD4 (0.71) | DRD4DRD2SIGMAR1BACE1BCHE | |
| SCHEMBL17961749 | 0.85 | DRD4 (0.70) | DRD4DRD2SIGMAR1BACE1BCHE | |
| SCHEMBL20183285 | 0.85 | DRD4 (0.70) | DRD4DRD2SIGMAR1BACE1BCHE | |
| SCHEMBL19614234 | 0.85 | DRD4 (0.70) | DRD4DRD2SIGMAR1BACE1BCHE | |
| SCHEMBL27890304 | 0.84 | DRD4 (0.50) | DRD4DRD2SIGMAR1MCHR1 | |
| SCHEMBL2349196 | 0.83 | DRD4 (0.54) | DRD4DRD2SIGMAR1ACHEMCHR1 | |
| SCHEMBL12280116 | 0.83 | DRD4 (0.54) | DRD4DRD2SIGMAR1ACHEMCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1404338-A1 | ADENOSINE ANALOGUES FOR THE TREATMENT OF THE INSULIN RESISTANCE SYNDROME AND DIABETES | Aventis Pharma Deutschland GmbH (DE) | 2004-04-07 | — | — | EP | disclosed |
| US-20030176390-A1 | Methods of treating insulin resistance syndrome and diabetes | HERLING ANDREAS (DE) | 2003-09-18 | — | — | US | disclosed |
| EP-0912520-B1 | COMPOUNDS HAVING ANTIHYPERTENSIVE, CARDIOPROTECTIVE, ANTI-ISCHEMIC AND ANTILIPOLYTIC PROPERTIES | AVENTIS PHARM PROD INC (US) | 2003-05-07 | — | — | EP | disclosed |
| US-6559313-B2 | Adenosine derivatives such as (1S,2R,3S,4R)-2,3-dihydroxy-4-(6-(1-(4-trifluormethylpyridin-2-yl)pyrrolidin-3(S)-yl-amino)purin-9-yl)cyclopentanecarboxylic acid isopropylamide | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-05-06 | — | — | US | disclosed |
| WO-2002092093-A1 | ADENOSINE ANALOGUES FOR THE TREATMENT OF THE INSULIN RESISTANCE SYNDROME AND DIABETES | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-11-21 | — | — | WO | disclosed |
| EP-1258247-A1 | Adenosine analogues for the treatment of insulin resistance syndrome and diabetes | Aventis Pharma Deutschland GmbH (DE) | 2002-11-20 | — | — | EP | disclosed |
| US-20020099030-A1 | Compounds having antihypertensive, cardioprotective anti-ischemic and antilipolytic properties | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-07-25 | — | — | US | disclosed |
| US-6376472-B1 | N6-SUBSTITUTED ADENOSINES | AVENTIS PHARMACEUTICALS, INC. | 2002-04-23 | — | — | US | disclosed |
| WO-2000023447-A1 | ADENOSINE ANALOGUES HAVING ANTIHYPERTENSIVE, CARDIOPROTECTIVE, ANTI-ISCHEMIC ANTILIPOLYTIC PROPERTIES | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 2000-04-27 | — | — | WO | disclosed |
| EP-0912520-A4 | COMPOUNDS HAVING ANTIHYPERTENSIVE, CARDIOPROTECTIVE, ANTI-ISCHEMIC AND ANTILIPOLYTIC PROPERTIES | RHONE POULENC RORER PHARMA (US) | 1999-10-06 | — | — | EP | disclosed |
| EP-0912520-A1 | COMPOUNDS HAVING ANTIHYPERTENSIVE, CARDIOPROTECTIVE, ANTI-ISCHEMIC AND ANTILIPOLYTIC PROPERTIES | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1999-05-06 | — | — | EP | disclosed |
| WO-1998001426-A1 | COMPOUNDS HAVING ANTIHYPERTENSIVE, CARDIOPROTECTIVE, ANTI-ISCHEMIC AND ANTILIPOLYTIC PROPERTIES | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176390-A1 | Methods of treating insulin resistance syndrome and diabetes | IAPP, GPR119, INSR | DRD4 3898/4885DRD2 3446/4885SIGMAR1 2143/4885 |
| US-20020099030-A1 | Compounds having antihypertensive, cardioprotective anti-ischemic and antilipolytic properties | HMGCR, TGFB1, APOB | DRD4 2038/4885DRD2 2470/4885SIGMAR1 3154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.